UnitedHealthcare Ohio policy CS103OH.C (March 1, 2026) now explicitly states prolotherapy (including hypertonic dextrose) and platelet-rich plasma (PRP) are unproven and not medically necessary for any musculoskeletal indication. The revision retains a detailed evidence review noting heterogeneous preparations, small/variable trials, inconsistent outcomes across knee OA, tendinopathies, rotator cuff disease, plantar fasciitis and low back pain, and limited safety/long-term data. Professional society guidance and high-quality RCTs showing no consistent benefit (e.g., Bennell et al., 2021) are cited to support the blanket noncoverage. Providers should continue to refer to related Ohio policies (e.g., skin and soft tissue substitutes) for other biologic injections.
March 2026 Revision: Coverage Determination Clarified
Summary of changes in this revision
The March 1, 2026 revision of UnitedHealthcare Medical Policy CS103OH.C clarifies coverage status for prolotherapy and platelet-rich plasma (PRP) across musculoskeletal indications. The Coverage Rationale now states explicitly that, "Due to insufficient evidence of efficacy, the following are unproven and not medically necessary for any condition or indication: - Prolotherapy - Platelet-rich plasma." This language confirms a blanket noncovered determination for these biologic and dextrose-based injection therapies within the scope of this orthopedics and musculoskeletal (MDC 08) policy for Ohio.
The revision also retains descriptive and evidentiary content summarizing the clinical literature across multiple indications (low back pain, osteoarthritis, tendinopathies, rotator cuff disease, plantar fasciitis, etc.), and preserves references to other UnitedHealthcare/Ohio policies (e.g., the note to refer to the Medical Policy titled "Skin and Soft Tissue Substitutes (for Ohio Only)" for amnion-derived fluid injections). The policy continues to document heterogeneity in preparations, variable trial quality, and the need for standardized protocols as rationale for the noncoverage determination.
Coverage Rationale: Blanket Noncoverage for Prolotherapy and PRP
Explicit coverage determination: prolotherapy and platelet-rich plasma are not medically necessary
The policy's Coverage Rationale states that both prolotherapy (including hypertonic dextrose and other injectates) and platelet-rich plasma (PRP) are "unproven and not medically necessary for any condition or indication." This is an across-the-board noncoverage statement rather than a conditional or indication-specific limitation. The policy text repeats this single, definitive determination at the start of the Coverage Rationale section.
The descriptive material that follows documents a broad and mixed evidence base across indications but is cited in support of the overall conclusion that evidence is insufficient to establish efficacy and standardized, reproducible clinical benefit. The policy also highlights lack of standardization of PRP formulations (platelet and leukocyte content, activation, number/timing of injections) and heterogeneous prolotherapy protocols as contributors to the noncoverage determination.
Evidence Overview: Methodological Limitations and Variable Outcomes
Evidence synthesis supporting the determination — heterogeneity and inconsistent outcomes across indications
The policy compiles systematic reviews, randomized controlled trials (RCTs), and observational studies across multiple musculoskeletal conditions and consistently notes methodological limitations: small samples, short follow-up, variable controls (saline, corticosteroid, hyaluronic acid, exercise), diverse injectate preparations, and inconsistent reporting of adverse events. For knee osteoarthritis (KOA), the policy cites large RCTs and multiple meta-analyses with mixed conclusions — some meta-analyses suggest PRP or dextrose prolotherapy may have modest benefit at certain time points, whereas high-quality RCTs (e.g., Bennell et al., 2021) showed no difference versus saline at 12 months. These mixed results are summarized as insufficient to support medical necessity.
For tendinopathies and lateral epicondylosis, several RCTs and meta-analyses are discussed that show short- to mid-term improvements in some trials (e.g., dextrose prolotherapy advantages vs saline or exercise in select studies), but systematic reviews consistently remark on small trials and heterogeneity. Similar heterogeneity and inconsistent long-term benefit are described for PRP across rotator cuff disease, plantar fasciitis, Achilles tendinopathy, and discogenic low back pain, with some RCTs indicating transient benefits but overall low to very low certainty of evidence.
Safety, Standardization Issues, and Guideline Context
Safety, standardization, and guideline positions reflected in policy
The policy notes that PRP preparations are not standardized and that safety data are limited, particularly for long-term outcomes beyond one year. Adverse event reporting in the cited literature is inconsistent; several trials and systematic reviews report transient post-injection pain as the most common event, with rare serious complications described in isolated reports. For prolotherapy, safety and efficacy data are similarly limited and heterogeneous.
Professional guidelines and position statements summarized in the policy are aligned with a cautious stance: the AAOS and AAHS guidance recognizes possible short-term benefit in some knee OA studies but calls for standardization and higher-quality trials; the American College of Rheumatology/Arthritis Foundation recommends against PRP and conditionally recommends against prolotherapy for hip/knee OA; the American Association of Hip and Knee Surgeons states biologics (including PRP) cannot currently be recommended for advanced arthritis. These external guideline positions are cited in the policy narrative and support the policy’s determination of insufficient evidence and noncoverage.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.